Vimarsana
Biggest News Aggregation in the World

Page 2 - Antipsychotics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Antipsychotics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Antipsychotics Today - Breaking & Trending Today

FOXNEWSW Jesse July 3, 2024 - Vimarsana News

FOXNEWSW Jesse July 3, 2024

His trial could have been primo, but theyited u waited till i was right in the middle of my campaignt in. Financial assassination. Youre next, ted. So, ireland, youve been making up your own visiting hours again. Get awa tuty from here. N makg but that may happen. Vivek ramaswamyoury says bringng back insane asylum. Hes here. Makes its own meatball, plays the race card. Plus. Oh, jesse, come chug a beer with me. Last night, the u. S. Attorney general told 60 minutes that washington doesnnutet care if youre rich poor, friend or foe, black or white. O republican or democrat, you gete treated the...

Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD - Vimarsana News

Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

John Kane, MD: Shifts in Antipsychotics for Schizophrenia - Vimarsana News

John Kane, MD: Shifts in Antipsychotics for Schizophrenia

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

Antipsychotic Drugs for Dementia Raise New Health Risks - Vimarsana News

Antipsychotic Drugs for Dementia Raise New Health Risks

A new study links antipsychotic medications for dementia patients with more serious health outcomes than previously known. Learn more about the risks.

Source: aarp.org
Novel Agent Curbs Alzheimer's-Related Agitation - Vimarsana News

Novel Agent Curbs Alzheimer's-Related Agitation

AXS-05, a combination of dextromethorphan and bupropion, led to a rapid and sustained improvement in agitation related to Alzheimer's disease in the phase 3 ACCORD trial.